secwatch.observer — SEC 8-K summary
======================================

Issuer:     KIORA PHARMACEUTICALS INC (KPRX)
CIK:        0001372514
Form:       8-K
Filed at:   2026-06-18T11:02:51+00:00
Accession:  0001372514-26-000063
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kiora reports KIO-300 suppresses seizure activity in preclinical epilepsy model
-------------------------------------------------------------------------------

- KIO-300 significantly reduced epileptiform event frequency in hippocampal CA1 slices (p<0.0001).
- Suppression persisted through treatment and washout; no impairment of normal electrical transmission.
- Data presented at Epilepsy Foundation Pipeline Conference, June 18-19, 2026 in Leesburg, VA.
- KIO-300 is the active ingredient of KIO-301, currently in Phase 2 for Retinitis Pigmentosa.
- CEO cites broad therapeutic potential beyond ophthalmology; full rights retained outside eye.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1372514/000137251426000063/0001372514-26-000063-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1372514/000137251426000063/kprx-20260618.htm
  HTML page:      https://secwatch.observer/filing/0001372514-26-000063

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer